Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:OTIC
- CUSIP: N/A
- Web: www.otonomy.com
Capitalization:- Market Cap: $571.21 million
- Outstanding Shares: 30,303,000
Average Prices:- 50 Day Moving Avg: $18.56
- 200 Day Moving Avg: $15.02
- 52 Week Range: $11.30 - $20.15
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.26
- P/E Growth: -0.28
Sales & Book Value:- Annual Revenue: $1.28 million
- Price / Sales: 446.26
- Book Value: $4.95 per share
- Price / Book: 3.81
Profitability:- EBIDTA: ($104,540,000.00)
- Net Margins: -8,172.38%
- Return on Equity: -57.43%
- Return on Assets: -53.65%
Debt:- Current Ratio: 16.33%
- Quick Ratio: 16.21%
Misc:- Average Volume: 193,803 shs.
- Beta: 2.79
- Short Ratio: 9.68
Frequently Asked Questions for Otonomy (NASDAQ:OTIC)
What is Otonomy's stock symbol?
Otonomy trades on the NASDAQ under the ticker symbol "OTIC."
How were Otonomy's earnings last quarter?
Otonomy, Inc. (NASDAQ:OTIC) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.03. The firm had revenue of $0.33 million for the quarter, compared to analysts' expectations of $0.43 million. Otonomy had a negative net margin of 8,172.38% and a negative return on equity of 57.43%. Otonomy's revenue for the quarter was up 312.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.98) earnings per share. View Otonomy's Earnings History.
Where is Otonomy's stock going? Where will Otonomy's stock price be in 2017?
2 equities research analysts have issued 12-month price targets for Otonomy's shares. Their forecasts range from $28.00 to $32.00. On average, they anticipate Otonomy's share price to reach $30.00 in the next twelve months. View Analyst Ratings for Otonomy.
Who are some of Otonomy's key competitors?
Some companies that are related to Otonomy include Acorda Therapeutics (ACOR), Neuroderm Ltd (NDRM), Omeros Corporation (OMER), Dermira (DERM), Xencor (XNCR), Retrophin (RTRX), Dynavax Technologies Corporation (DVAX), Sangamo Therapeutics (SGMO), Aduro Biotech (ADRO), Epizyme (EPZM), Amarin Corporation PLC (AMRN), Keryx Biopharmaceuticals (KERX), Five Prime Therapeutics (FPRX), Achaogen (AKAO), Insmed (INSM), PTC Therapeutics (PTCT), ZIOPHARM Oncology (ZIOP) and Revance Therapeutics (RVNC).
Who are Otonomy's key executives?
Otonomy's management team includes the folowing people:
- Jay Lichter Ph.D., Independent Chairman of the Board
- David A. Weber Ph.D., President, Chief Executive Officer, Director
- Paul E. Cayer, Chief Financial and Business Officer
- Robert Michael Savel II, Chief Technical Officer
- Kathie M. Bishop Ph.D., Chief Scientific Officer
- Eric J. Loumeau, Chief Compliance Officer, General Counsel, Secretary
- Dean Hakanson M.D., Chief Medical Officer
- Vickie L. Capps, Independent Director
- Iain R. McGill, Independent Director
- George J. Morrow, Independent Director
Who owns Otonomy stock?
Otonomy's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (11.90%), TPG Group Holdings SBS Advisors Inc. (7.13%), Federated Investors Inc. PA (5.92%),
ORBIMED ADVISORS LLC
(4.62%), Vanguard Group Inc. (3.14%) and FMR LLC (2.41%). Company insiders that own Otonomy stock include Carl Lebel, Chau Quang Khuong, David Allen Weber, Eric J Loumeau, Orbimed Advisors Llc, Paul E Cayer and Robert Michael Savel II. View Institutional Ownership Trends for Otonomy.
Who sold Otonomy stock? Who is selling Otonomy stock?
Otonomy's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Columbus Circle Investors, Federated Investors Inc. PA, Vanguard Group Inc., Schroder Investment Management Group, Goldman Sachs Group Inc., State Street Corp and Citadel Advisors LLC. Company insiders that have sold Otonomy stock in the last year include Carl Lebel and Eric J Loumeau. View Insider Buying and Selling for Otonomy.
Who bought Otonomy stock? Who is buying Otonomy stock?
Otonomy's stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Dimensional Fund Advisors LP, Alliancebernstein L.P., Northern Trust Corp, TD Asset Management Inc., State of Wisconsin Investment Board, Schwab Charles Investment Management Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for Otonomy.
How do I buy Otonomy stock?
Shares of Otonomy can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Otonomy's stock price today?
One share of Otonomy stock can currently be purchased for approximately $18.85.
MarketBeat Community Rating for Otonomy (NASDAQ OTIC)MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Otonomy (NASDAQ:OTIC)Earnings History by Quarter for Otonomy (NASDAQ OTIC)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/3/2017 | Q2 2017 | ($0.80) | ($0.77) | $0.43 million | $0.33 million | View | Listen |  |
| 5/4/2017 | Q1 2017 | ($0.84) | ($0.89) | $0.50 million | $0.36 million | View | Listen | |
| 3/2/2017 | Q4 2016 | ($0.93) | ($0.88) | $0.49 million | $0.27 million | View | Listen | |
| 3/7/2016 | Q4 | ($0.95) | ($0.87) | | | View | Listen | |
| 11/10/2015 | Q315 | ($0.83) | ($0.57) | | | View | N/A | |
| 8/12/2015 | Q116 | ($0.67) | ($0.52) | | | View | N/A | |
| 5/12/2015 | Q115 | ($0.53) | ($0.52) | | | View | N/A | |
| 3/18/2015 | Q415 | ($0.64) | ($0.46) | | | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Otonomy (NASDAQ:OTIC)Current Year EPS Consensus Estimate: $-3.36 EPS
Next Year EPS Consensus Estimate: $-3.01 EPS
Dividend History for Otonomy (NASDAQ:OTIC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Otonomy (NASDAQ:OTIC)Insider Ownership Percentage: 12.70%
Institutional Ownership Percentage: 88.46%
Insider Trades by Quarter for Otonomy (NASDAQ:OTIC)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/26/2017 | Eric J. Loumeau | Insider | Sell | 3,522 | $18.59 | $65,473.98 | |
| 11/21/2016 | Carl Lebel | Insider | Sell | 10,625 | $18.07 | $191,993.75 | |
| 12/21/2015 | Carl Lebel | insider | Sell | 21,250 | $28.04 | $595,850.00 | |
| 12/17/2015 | Paul E. Cayer | insider | Sell | 3,000 | $29.70 | $89,100.00 | |
| 12/15/2015 | David Allen Weber | CEO | Sell | 5,208 | $27.25 | $141,918.00 | |
| 12/14/2015 | Robert Michael Savel II | insider | Sell | 5,000 | $26.00 | $130,000.00 | |
| 11/30/2015 | Chau Quang Khuong | Director | Sell | 67,106 | $28.93 | $1,941,376.58 | |
| 11/24/2015 | Orbimed Advisors Llc | Director | Sell | 200,800 | $28.56 | $5,734,848.00 | |
| 11/19/2015 | Chau Quang Khuong | Director | Sell | 138,398 | $28.62 | $3,960,950.76 | |
| 11/17/2015 | Paul E. Cayer | insider | Sell | 3,000 | $28.69 | $86,070.00 | |
| 11/16/2015 | David Allen Weber | CEO | Sell | 5,208 | $28.57 | $148,792.56 | |
| 11/13/2015 | David Allen Weber | CEO | Sell | 10,416 | $30.95 | $322,375.20 | |
| 11/11/2015 | David Allen Weber | CEO | Sell | 5,208 | $24.95 | $129,939.60 | |
| 11/11/2015 | Paul E. Cayer | CFO | Sell | 3,000 | $24.95 | $74,850.00 | |
| 9/21/2015 | Carl Lebel | insider | Sell | 21,250 | $24.36 | $517,650.00 | |
| 9/17/2015 | Paul E. Cayer | CFO | Sell | 3,000 | $24.95 | $74,850.00 | |
| 9/15/2015 | David Allen Weber | CEO | Sell | 5,216 | $24.95 | $130,139.20 | |
| 9/14/2015 | Robert Michael Savel II | insider | Sell | 5,000 | $23.98 | $119,900.00 | |
| 6/15/2015 | Robert Michael Savel II | Insider | Sell | 25,000 | $23.73 | $593,250.00 | |
| 8/19/2014 | A/S Novo | Insider | Buy | 15,690 | $15.50 | $243,195.00 | |
| 8/18/2014 | A/S Novo | Insider | Buy | 171,875 | $16.00 | $2,750,000.00 | |
| 8/18/2014 | Jay Lichter | Director | Sell | 50,001 | $16.00 | $800,016.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Otonomy (NASDAQ:OTIC)
Latest Headlines for Otonomy (NASDAQ:OTIC)
| Source: |
|
| Date | Headline |
|---|
 | Otonomy, Inc. (OTIC) Upgraded at J P Morgan Chase & Co
www.americanbankingnews.com - August 15 at 8:02 PM |
| BidaskClub Downgrades Otonomy, Inc. (OTIC) to Hold
www.americanbankingnews.com - August 13 at 12:44 AM |
 | Otonomy, Inc. breached its 50 day moving average in a Bearish Manner : OTIC-US : August 10, 2017
finance.yahoo.com - August 11 at 7:19 AM |
| Otonomy, Inc. (NASDAQ:OTIC) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 4 at 5:46 PM |
| Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 4 at 6:45 AM |
| Head to Head Contrast: Otonomy (NASDAQ:OTIC) and Kite Pharma (KITE)
www.americanbankingnews.com - July 29 at 8:21 AM |
| Otonomy to Report Second Quarter 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - July 28 at 6:31 AM |
| Is the Options Market Predicting a Spike in Otonomy (OTIC) Stock?
finance.yahoo.com - July 26 at 6:11 AM |
 | Otonomy (OTIC) sNDA for OTIPRIO Accepted by FDA
www.streetinsider.com - July 19 at 2:02 AM |
| Otonomy Announces FDA Acceptance of OTIPRIO® Supplemental New Drug Application Filing for Acute Otitis Externa
finance.yahoo.com - July 19 at 2:02 AM |
| Otonomy, Inc. (OTIC) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - June 30 at 7:12 PM |
| Implied Volatility Surging for Otonomy (OTIC) Stock Options
finance.yahoo.com - June 28 at 2:57 PM |
| Eric J. Loumeau Sells 3,522 Shares of Otonomy, Inc. (OTIC) Stock
www.americanbankingnews.com - June 27 at 7:51 PM |
| Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acute Otitis Media with Tympanostomy Tubes
finance.yahoo.com - June 23 at 8:52 AM |
| Otonomy to Host Key Opinion Leader Meeting for Investors on Ménière's Disease
finance.yahoo.com - June 21 at 1:20 AM |
| ETFs with exposure to Otonomy, Inc. : June 15, 2017
finance.yahoo.com - June 16 at 8:38 AM |
| Otonomy, Inc. breached its 50 day moving average in a Bullish Manner : OTIC-US : June 12, 2017
finance.yahoo.com - June 12 at 6:46 PM |
| Otonomy, Inc. breached its 50 day moving average in a Bullish Manner : OTIC-US : June 2, 2017
finance.yahoo.com - June 2 at 9:21 PM |
| Piper Jaffray Companies Initiates Coverage on Otonomy Inc (OTIC)
www.americanbankingnews.com - June 2 at 10:10 AM |
| ETFs with exposure to Otonomy, Inc. : May 23, 2017
finance.yahoo.com - May 23 at 6:33 PM |
| Otonomy Inc (OTIC) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 18 at 8:26 PM |
| Zacks Investment Research Downgrades Otonomy Inc (OTIC) to Hold
www.americanbankingnews.com - May 14 at 8:58 PM |
| Otonomy Announces OTIPRIO® Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting
finance.yahoo.com - May 12 at 8:26 AM |
| ETFs with exposure to Otonomy, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 7:34 PM |
| Otonomy to Present at the Bank of America Merrill Lynch Health Care Conference
finance.yahoo.com - May 10 at 7:17 PM |
| Otonomy, Inc. :OTIC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 11:50 AM |
 | Noteworthy Tuesday Option Activity: OTIC, YELP, NVDA
www.nasdaq.com - May 9 at 6:39 PM |
| SunTrust Banks Weighs in on Otonomy Inc's FY2021 Earnings (OTIC)
www.americanbankingnews.com - May 8 at 12:28 PM |
| Otonomy Inc (OTIC) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - May 7 at 6:26 PM |
| Otonomy Inc (OTIC) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - May 5 at 4:40 PM |
 | Otonomy reports 1Q loss
marketbeat.com - May 4 at 7:17 PM |
| Investor Network: Otonomy, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 7:16 PM |
| Otonomy Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 4 at 7:16 PM |
| Otonomy (OTIC) Earning Favorable Media Coverage, Report Finds
www.americanbankingnews.com - May 3 at 6:26 PM |
| Otonomy (OTIC) Getting Positive Press Coverage, Study Shows
www.americanbankingnews.com - April 29 at 6:33 PM |
| Otonomy, Inc. – Value Analysis (NASDAQ:OTIC) : April 28, 2017
finance.yahoo.com - April 28 at 8:09 PM |
| Otonomy to Report First Quarter 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - April 27 at 7:33 PM |
| Otonomy, Inc. breached its 50 day moving average in a Bullish Manner : OTIC-US : April 27, 2017
finance.yahoo.com - April 27 at 10:18 AM |
| Otonomy (OTIC) Receives News Sentiment Rating of 0.24
www.americanbankingnews.com - April 26 at 7:52 PM |
| Otonomy (OTIC) Receiving Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 22 at 1:59 PM |
| Otonomy (OTIC) Earning Very Positive News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 18 at 10:23 AM |
| Commit To Buy Otonomy At $10, Earn 10.1% Annualized Using Options
www.nasdaq.com - April 8 at 6:20 PM |
| Short Interest in Otonomy Inc (OTIC) Grows By 8.7%
www.americanbankingnews.com - April 5 at 10:52 PM |
| Edited Transcript of OTIC earnings conference call or presentation 2-Mar-17 9:30pm GMT
finance.yahoo.com - March 31 at 7:13 PM |
 | 5 Biotech Stocks That Could Skyrocket From Upcoming Catalysts
247wallst.com - March 21 at 11:10 AM |
| OTONOMY, INC. Financials
finance.yahoo.com - March 8 at 3:45 PM |
| Otonomy reports 4Q loss - Yahoo Finance
finance.yahoo.com - March 3 at 12:18 AM |
 | Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
us.rd.yahoo.com - March 2 at 7:17 PM |
| 4:27 pm Otonomy reports Q4, issues guidance
us.rd.yahoo.com - March 2 at 7:17 PM |
| Q4 2016 Otonomy Inc Earnings Release - After Market Close
biz.yahoo.com - March 2 at 8:46 AM |
Otonomy (OTIC) Chart for Thursday, August, 17, 2017
